COMUNICADO: Rienso® (ferumoxitol) ofrece una nueva opción de tratamiento para pacientes renales (y 2)

[TAB]

1) Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron

deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605.

2) AMAG Pharmaceuticals. Datos archivados.

3) Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron

replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 386-393.

4) Schiller B, Bhat P, Sharma A, et al. Safety of Feraheme(R) (Ferumoxytol) in

hemodialysis patients at 3 dialysis chains over a 1-year period. J Am Soc Nephrol

2011; 22: 477A-478A. Abstr FR-PO1573.

5) Sharma A, Bhat P, Schiller B, et al. Efficacy of Feraheme(R) (Ferumoxytol)

administration on target hemoglobin levels and other iron parameters across 3 dialysis

chains. J Am Soc Nephrol 2011; 22: 485A. Abstr FR-PO1603.

6) Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge.

Lancet 2005; 365: 331-340.

7) Qunibi WY. The efficacy and safety of current intravenous iron preparations

for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010;

60: 399-412.

8) Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the

primary care setting: cardiovascular outcomes and management recommendations.

Osteopath Med Prim Care 2007; 1: 14.

9) O'Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectrum

2008; 21: 12-19.

10) National Kidney Foundation. KDOQI clinical practice guidelines and clinical

practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;

47:S11-15.

[FTAB]

CONTACTO: Para consultas de medios: Danny Stepto, Takeda: +41-79-609-9452,danny.stepto@takeda.com.